2,2-dimethyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)propanamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,2-dimethyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)propanamide
• 化学式: C₈H₁₃N₃OS
• mdl: MFCD00660359
• 分子量: 199.28
• InChiKey: WEOPFFBYLHFRJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• TETRACYCLIC COMPOUND
  申请人：Yamamoto Junichiro

  公开号：US20110112299A1

  公开（公告）日：2011-05-12

  Provided are a tetracyclic compound represented by the formula (I): [in the formula (I), the formula (A) represents a benzene ring or the like, X represents CH or a nitrogen atom, Q represents —O— or the like, R 1 , R 2 , and R 3 may be the same or different and each represent a hydrogen atom or the like, l, m, and n each represent an integer from one to the maximum substitutable number of substituents, and R 4 and R 5 may be the same or different and each represent a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof, and the like.

  提供的是一个四环化合物，其化学式表示为(I)：[在化学式(I)中，式(A)表示苯环或类似物，X表示CH或氮原子，Q表示-O-或类似物，R1、R2和R3可以相同也可以不同，每个都表示氢原子或类似物，l、m和n每个表示从1到可替代取代基的最大数的整数，R4和R5可以相同也可以不同，每个都表示氢原子或类似物]，或其药学上可接受的盐等。
• Triazolopyridine inhibitors of myeloperoxidase
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10316035B2

  公开（公告）日：2019-06-11

  The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了式(I)化合物：其中A、Y和R1各自如说明书中所定义，以及包含任何此类新型化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• Cycloalkyl-linked diheterocycle derivatives
  申请人：Pfizer Inc.

  公开号：US10676471B2

  公开（公告）日：2020-06-09

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式 (I) 的化合物 或其药学上可接受的盐，其中 A、L、D、R1-R15、w、x、y 和 z 在本文中定义。本发明的新型环烷基连环二杂环衍生物可用于治疗哺乳动物的异常细胞生长，如癌症。本发明还涉及含有这些化合物的药物组合物，以及使用这些化合物和组合物治疗哺乳动物异常细胞生长的方法。
• SEPIAPTERIN REDUCTASE INHIBITORS
  申请人：QUARTET MEDICINE, INC.

  公开号：US20170096435A1

  公开（公告）日：2017-04-06

  Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
• Cycloalkyl-Linked Diheterocycle Derivatives
  申请人：Pfizer Inc.

  公开号：US20190270737A1

  公开（公告）日：2019-09-05

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R 1 -R 15 , w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.